Actelion Ltd. (OTCMKTS:ALIOF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Actelion Limited is an independent, profitable, biopharmaceutical company discovering, developing and marketing drugs for high unmet medical needs. “

Actelion Company Profile

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/actelion-ltd-aliof-downgraded-to-hold-at-zacks-investment-research.html

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Get a free copy of the Zacks research report on Actelion (ALIOF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actelion Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.